Diffusion Pharmaceuticals... (DFFN)
4.40
0.41 (10.28%)
At close: Aug 16, 2023, 8:00 PM
Company Description
Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen.
Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease.
Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.
Diffusion Pharmaceuticals Inc.
| Country | United States |
| IPO Date | May 23, 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Dr. Robert J. Cobuzzi Jr., Ph.D. |
Contact Details
Address: 300 East Main Street Charlottesville, Virginia United States | |
| Website | https://www.diffusionpharma.com |
Stock Details
| Ticker Symbol | DFFN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001053691 |
| CUSIP Number | 253748305 |
| ISIN Number | US15713L1098 |
| Employer ID | 30-0645032 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Robert J. Cobuzzi Jr., Ph.D. | Pres & Chief Executive Officer |
| William Karl Hornung | Chief Financial Officer |
| Brian D. Bollwage | Senior Consultant - Regulatory Affairs |
| Douglas Gravatt | Senior Consultant for Manufacturing |
| Dr. Christopher D. Galloway M.D. | Chief Medical Officer |
| Dr. David Randolph Jones M.D. | Senior Medical Advisor |
| Dr. Jennifer Llewelyn Ph.D. | Senior Director & Head of CMC |
| Harry Cook | Vice President of Clinical Operations |
| Kelly Hoy | Director of Project Management |
| Raven Jaeger M.S. | Chief Regulatory Officer |
| Suzanne Cassidy | Senior Director & Head of Quality Assurance |
| William Robert Elder J.D. | Gen. Counsel & Corporation Sec. |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 18, 2025 | 8-K | Current Report |
| Apr 07, 2025 | 8-K | Current Report |
| Mar 18, 2025 | 8-K | Current Report |
| Mar 17, 2025 | S-8 | Filing |
| Mar 17, 2025 | 10-K | Annual Report |
| Mar 11, 2025 | 8-K | Current Report |
| Mar 10, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Feb 14, 2025 | 4 | Filing |
| Feb 14, 2025 | 4 | Filing |